ABOUT US
TECHNOLOGY
- EXACT Technology
- Manufacturing
PIPELINE
- Partnerships
- Clinical Trials
PATIENTS AND FAMILIES
INVESTORS
CAREERS
CONTACT US
TWITTER
LINKEDIN
FACEBOOK

Focusing on the Future of Life-Changing Genetic Medicines

Gene therapy holds incredible promise to revolutionize medical treatment. At Neurogene we believe that innovation, robust scientific execution, and a strong sense of purpose are required to turn this promise into reality. Our focus is to develop life-changing genetic medicines for people and their families impacted by devastating neurological diseases.

Learn More >>

OUR PIPELINE

We are building a gene therapy pipeline to help address the high unmet need for rare neurological diseases.

LEARN MORE

ABOUT US

At Neurogene, we are driven by a strong sense of purpose to advance genetic medicines.

LEARN MORE

LATEST NEWS

Neurogene Reports Second Quarter 2024 Financial Results and Highlights Recent Updates

NGN-401 gene therapy for Rett syndrome received RMAT designation from FDA based on preliminary clinical evidence indicating the potential to…

Neurogene Announces RMAT Designation for NGN-401 Investigational Gene Therapy for Rett Syndrome

Designation based on preliminary clinical evidence from ongoing NGN-401 clinical trial that shows potential to address unmet medical needs in…

Neurogene to Participate in BMO Genetic Medicines Summit

NEW YORK --(BUSINESS WIRE)--Jul. 2, 2024-- Neurogene Inc. (NASDAQ: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to…